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(2) These effects of EPC-MVs were accompanied with a reduction of ROS production,
which could be abolished or partially blocked by PI3K or NOS inhibitor, and with
protein up-regulations in Akt/P-Akt and its downstream eNOS/P-eNOS; (3) Depletion
of RNAs from EPC-MVs partially eliminated the protective effects of EPC-MVs.
Conclusions: Our data indicate that EPC-MVs can protect H9c2 CMs from Ang
II-induced hypertrophy and apoptosis through the activation of PI3K/Akt/eNOS
signaling pathway, at least partly via the mediation of the RNAs carried by them.
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Objectives: To observe transmural heterogeneity of ventricular repolarization and
CX43 protein in chronic heart failure (CHF), and electrophysiological and molecular
mechanisms of malignant ventricular arrhythmia (MVA) in the CHF.
Methods: All rabbits were randomly divided into CHF group which was made with
traditional abdominal aorta constriction method and sham operation group. Ventric-
ular ﬁbrillation threshold (VFT), 90% monophasic action potential repolarization
duration (APD90) of subepicardial, midmyocardial and subendocardial myocardium,
transmural dispersion of repolarization (TDR) and CX43 protein expression in three
layers of myocardium were measured in both groups.
Results: There was a signiﬁcant difference between the sham operation group and the
CHF group [(13.151.88) & (7.461.22) V, P<0.01]. APD90 of three myocardial
layers in the CHF group were signiﬁcantly prolonged more than those in the sham
operation group (P<0.01). DAPD90 and TDR in the CHF group were signiﬁcantly
higher than those in the sham operation group (P<0.05). CX43 protein expression of
all three myocardial layers were decreased obviously in the CHF group (P<0.05), but
reduction was more signiﬁcant in the midmyocardium.
Conclusions: Increased transmural heterogeneity of CX43 expression may enlarge
dispersion of repolarization across ventricular wall and easy to induce MVA in CHF.
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Objectives: The liver X receptors are ligand-dependent transcription factors that have
been implicated in the control of cholesterol and fatty acid metabolism as well as
macrophage inﬂammatory gene expression. Oxidized low-density lipoprotein induced
endothelial inﬂammation is the initial step during pathogenesis of atherosclerosis
which trigger the expression of adhesion molecular and the secretion of chemokine in
endothelial cell to recruitment of monocyte/macrophages. Although the ligand of liver
X receptor are known to regress atherosclerosis in mouse models, their ability to
control the endothelial inﬂammatory induced by OxLDL has not been addressed.
Methods: We evaluated the macrophage inﬁltration of aortic sinus in apoE-/- mice
intravenous injected with the ligand of liver X receptor GW3965 or control using
immunohistochemistry. HUVECs were treated with lysophosphatidylcholine (LPC), a
major chemotactic lipid component of oxLDL, after the incubation of GW3965 or
vehicle. The secretion of chemokine and the activity of NF-kB pathway were
measured by ELISA, Western Blot and the NF-kB (p65) Transcription Factor Assay
Kit. In addition, we also knocked down UBC9 and HDAC4, indispensable small
ubiquitin-like modiﬁer (SUMO) ligase, mediated by siRNA to evaluate the modiﬁ-
cation of SUMOylation in this suppression of liver X receptor.
Results: Fewer macrophages were present in the aortas of apoE-/- mice and the
quantitative analysis revealed signiﬁcantly less MOMA-2-positive staining in
GW3965 treatment group than in the control (P<0.05). And the levels of IL-8 in
supernatant of HUVECs at each time and concentration point were markly elevated in
the LPC treatment group relative to the Control (P<0.05), whereas signiﬁcant de-
creases (P<0.02) were observed in GW3965 and LPC treatment group. Western Blot
clearly revealed GW3965 decreased the phosphorylation of IKK-alpha/beta and IKB-
alpha. What’s more, the NF-kB (p65) Transcription Factor Assay Kit also indicated
GW3965 inhibited p65 binding to IL-8 gene promoters in LPC-stimulated HUVECs.
In addition, knockdown of UBC9 or HDAC4 abrogated the effects of GW3965 on
antagonizing LPC-induced IL-8 overexpression.
Conclusions: These ﬁndings suggest that the ligand of liver X receptor activates
SUMOylation and inhibits NF-kB activation in LPC-stimulated HUVECs, which in
turn decrease chemokines expression. The results unveil a new mechanism triggered
by liver X receptor for prevention of atherosclerosis.
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Hospital, Xi-ning, Qinghai Province, 810007, ChinaJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/BObjectives: To study expression of connexin 43 (Cx43) in Smooth muscle cells of
Non-culprit arteries and role of angiotensin II in expression of connexin 43.
Methods: Myocardial ischemia-reperfusion model in rabbit was prepared; ﬂuores-
cence immunohistochemistry analytical method was used to semiquantitative analysis
for Cx43 in Smooth muscle cells of non-infarction related arteries. Smooth muscle
cells in non-infarction related arteries were isolated and cultured, Smooth muscle cells
were divided into 4 groups (12 samples in each group) at random: (1) normal control
group. (2) Hyperlipidemia control group. (3) angiotensin II (Ang II) intervention
group: smooth muscle cells were stimulated with 110-7mol/L Ang II for 24 h. (4)
MARK signal transduction pathway inhibitor pretreatment and Ang II intervention
group:inhibitor (PD98059 (100mmol/L), SP600125 (25mmol/L), SB203580 (25mmol/
L) ) pretreatment for 30 min before the addition of Ang II for 24 h. Expression of
Cx43 in each group was analysised.
Results: Expression of Cx43 in hyperlipidemia control group was higher than that in
normal control group (1.250.21 vs 0.620.14, P<0.05); Expression of Cx43 in Ang
II intervention group was higher than that in hyperlipidemia control group (1.790.31
vs 1.250.21, P<0.05); Expression of Cx43 in MARK signal transduction pathway
inhibitor pretreatment and Ang II intervention group was lower than that in Ang II
intervention group[(0.850.19 vs 1.790.31, P<0.05), (0.990.13 vs 1.790.31,
P<0.05), (0.810.15 vs 1.790.31, P<0.05) respectively].
Conclusions: Expression of Cx43 in Smooth muscle cells of Non-culprit arteries may
be increase,and it may be involved in Ang II - MARK signal transduction pathway.
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Objectives: To study the effects of rosuvastatin on the expression of vascular cell
adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs)
injured by homocysteine (HCY).
Methods: The HUVECs were primary cultured. HUVECs from the second to fourth
generations were stimulated with different concentrations of HCY (range from
0.2mmol/lw1.2 mmol/l). The model of cell injury was set up with the concentration of
HCY 0.6mmol/l. Then the HUVECs were pretreated with rosuvastatin in different
concentration for 2 hours before HCY is added. The expression of VCAM-1 mRNA
was evaluated by real time-PCR. The content of VCAM-1 protein was detected with
western blot, and mevalonate (MEV) was added to evaluate whether the effect of
rosuvastatin on expression of VCAM-1 can be blocked.
Results: Hcy with concentration above 0.6mmol/L could effectively injure HUVECs
after 24 hours. Damage degree was dose dependent. Rosuvastatin with concentration
of 1.0mmol/L and 2.0mmol/L can effectively reverse the injury induced by 0.6mmol/
L Hcy. In HCY group, the content of VCAM-1 protein and the expression of VCAM-
1 mRNA was increased signiﬁcantly (P<0$05). In Rosuvastatin group, the content of
ICAM-1 protein and the mRNA expression of ICAM-1 was signiﬁcantly decreased
(P<0$05). The effects of Rosuvastatin on VCAM-1 protein can’t be blocked by
mevalonate.
Conclusions: Hcy can damage the HUVECs through the process of inﬂammation.
Rosuvastatin has shown the protective effect against the damage induced by Hcy
through the anti-inﬂammatory effect. Rosuvastatin have the function of anti-athero-
sclerosis by inhibiting the expression of ICAM-1 induced by HCY in HUVECs, and
the effect is independent on its lipid-lowering effect.
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Objectives: As a novel candidate gene contributing to primary aldosteronism (PA),
KCNJ5 gene is believed to play roles in adrenal hyperplasia. The present study aims to
explore the association of variants in KCNJ5 gene with CT scan-based adrenal hy-
perplasia in patients with PA from Xinjiang.
Methods: Followed the guideline of PA in 2008, a protocol for PA screening and
diagnosis was performed in Center of hypertension in Xinjiang from 2008 to 2010.
Finally, 457 cases of subjects with conﬁrmed PA were enrolled and were divided into
adrenal hyperplasia group and control group according to the ﬁndings of thin-section
CT scan. The blood samples were collected for DNA extraction and genotype
identiﬁcation.
Results: (1) The average level of plasma potassium in patients with adrenal hyperplasia
was (3.630.42) mmol/L, which was signiﬁcantly lower than that in controls
(3.760.37) mmol/L with P¼0.001. But the baseline plasma aldostrone level
(22.7826.52) ng/dl, urine potassium excretion (46.0222.47) mmol/L in the adrenal
hyperplasia group was higher than those in controls, which was (18.137.60) ng/dl,
P¼0.032) and (42.3715.66) mmol/L, P¼0.080). The age, mean blood pressure, body
mass index, plasma sodium, urine sodium excretion as well as plasma rennin activity
was matched. (2) 41.3% subjects were diagnosed as obstructive sleep apnea syndrome,asic and Translational Medicine C45
